NCT05539677招募中不适用
Analysis of the Immunogenetic Profile of Patients With Aggressive Course of Malignant Neoplastic Process Resistant to the Standard Treatment Approaches: a Translational Study
N.N. Petrov National Medical Research Center of Oncology1 个研究点 分布在 1 个国家目标入组 1,000 人开始时间: 1998年9月最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 1,000
- 试验地点
- 1
- 主要终点
- Progression in 3 mo
研究概览
简要总结
The investigators will collect biosamples of patient blood and tumour tissue for further immunological analysis of blood cell subpopulations, immunosupressive factors concentration, HLA expression an lymphocytes and tumour tissue, and and cancer testis antigenes expression on tumour cells, as well as clinical data on patient's stage, therapy, response and demographics. Possible prognostic and predictive dynamic biomarkers will be discovered for individualisation of treatment strategies
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 1 Year 至 —（Child, Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed inform consent
- •Histolgically verified solid tumour
- •Receiving systemic therapy for neoplasm
- •Has archival tumour tissue
- •Provide biosamples with living tumour tissue or blood samples for immunologic assessment
排除标准
- •Concurrent Lymphoprolipherative disorder
- •Patients after stem cell or bone marrow thansplantation
- •Incomplete informaton on previous cancer history or medical history
- •Patients with known primary immunodeficiency
- •Patients receiving immunosupressive therapy for concurrent illness
- •Pregnant patients
结局指标
主要结局
Progression in 3 mo
时间窗: 3 month
Presence of disease progression within 3 mo from sample aquisition
次要结局
- Overall survival (OS)(Up to 5 years)
- Response rate(During the intervention)
- Progression free survival(Up to 5 years)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
不适用
Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant DiseaseMalignant NeoplasmsHereditary Neoplastic SyndromesKidney CancerRenal CancerBladder CancerNCT00026884National Cancer Institute (NCI)5,950
已完成
不适用
BIO-CHECKPOINT 0 Biomarkers to Identify Oncology Patients on ICPI at Greater Risk of irAENeoplasmsNCT06247865Portsmouth Hospitals NHS Trust120
尚未招募
不适用
Genetic Investigation of Cancer PredispositionGenetic PredispositionCancerNCT04620278The University of Texas Health Science Center at San Antonio100
已完成
不适用
Immune-Related Adverse Events and Associated Biomarkers in Patients Receiving Cancer ImmunotherapyImmune-related Adverse EventCancerNCT06089967Duke University30
已完成
不适用
Selecting Specific Bio-markers and Researching Mechanisms of Immune Regulation From Inhalation Injury and Traumatic Lung Injury Based on Single Cell Sequencing TechnologyTraumatic Lung InjuryInhalation InjuryNCT05718830Changhai Hospital21